Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer

Alexander Sebastian Franzén,Abdelhadi Boulifa,Clarissa Radecke,Sebastian Stintzing,Martin J. Raftery,Gabriele Pecher
DOI: https://doi.org/10.3390/cancers16020388
2024-01-17
Cancers
Abstract:Colorectal carcinoma (CRC) presents a formidable medical challenge, demanding innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy has emerged as a promising alternative to CAR T-cell therapy for cancer. A suitable tumor antigen target on CRC is carcinoembryonic antigen (CEA), given its widespread expression and role in tumorigenesis and metastasis. CEA is known to be prolifically shed from tumor cells in a soluble form, thus hindering CAR recognition of tumors and migration through the TME. We have developed a next-generation CAR construct exclusively targeting cell-associated CEA, incorporating a PD1-checkpoint inhibitor and a CCR4 chemokine receptor to enhance homing and infiltration of the CAR-NK-92 cell line through the TME, and which does not induce fratricidal killing of CAR-NK-92-cells. To evaluate this therapeutic approach, we harnessed intricate 3D multicellular tumor spheroid models (MCTS), which emulate key elements of the TME. Our results demonstrate the effective cytotoxicity of CEA-CAR-NK-92 cells against CRC in colorectal cell lines and MCTS models. Importantly, minimal off-target activity against non-cancerous cell lines underscores the precision of this therapy. Furthermore, the integration of the CCR4 migration receptor augments homing by recognizing target ligands, CCL17 and CCL22. Notably, our CAR design results in no significant trogocytosis-induced fratricide. In summary, the proposed CEA-targeting CAR-NK cell therapy could offer a promising solution for CRC treatment, combining precision and efficacy in a tailored approach.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to overcome the obstruction of the tumor microenvironment (TME) to immune cell therapy in the treatment of colorectal cancer (CRC). Specifically, the researchers have developed a new chimeric antigen receptor (CAR) natural killer (NK) cell therapy, namely CEA - CAR - NK - 92 cells, aiming at colorectal cancer cells expressing carcinoembryonic antigen (CEA) and improving the treatment effect by enhancing the cell's migration and penetration ability towards tumor tissues. ### Main problems and solutions: 1. **Challenges of the tumor microenvironment**: - The tumor microenvironment is a complex ecosystem that contains multiple cell types and molecular signals. These factors can inhibit the function of immune cells, thus protecting the tumor from immune attacks. - To overcome this challenge, the researchers added PD1 checkpoint inhibitor (PD1x) and chemokine receptor CCR4 in the CAR design to enhance the migration ability and tumor - recognition ability of CAR - NK cells. 2. **Selection of CEA as a target**: - CEA is a glycoprotein over - expressed in multiple epithelial tumors, especially in colorectal cancer. It is related to tumor differentiation, invasion, and metastasis, so it is an ideal treatment target. - However, CEA can also be shed from the tumor cell surface in a soluble form, which may interfere with CAR recognition and function. For this reason, the researchers designed a CAR specifically targeting cell - surface - bound CEA, avoiding the influence of soluble CEA. 3. **Design and functional verification of CAR - NK cells**: - The researchers used the NK - 92 cell line as effector cells. This cell line has the characteristics of being easy to be genetically engineered and having unlimited proliferation, which is suitable for standardized production. - By constructing a new CAR structure containing CEA - CAR, PD1x, and CCR4, the researchers verified its killing ability against colorectal cancer cells and low off - target effect in multiple in vitro experiments. 4. **Application of 3D multicellular tumor sphere model**: - Traditional 2D cell culture models cannot fully simulate the complex environment of tumors in vivo. Therefore, the researchers used the 3D multicellular tumor spheroids (MCTS) model, which can better reflect the characteristics of the tumor microenvironment, such as nutrient deprivation, metabolite accumulation, hypoxia, pH change, and physical matrix barrier. - By testing the killing effect of CEA - CAR - NK - 92 cells in the MCTS model, the researchers proved the effectiveness and functionality of this therapy. ### Summary: The main goal of this paper is to develop a CEA - CAR - NK - 92 cell therapy that can effectively overcome the obstacles of the tumor microenvironment for the treatment of colorectal cancer. By adding PD1x and CCR4 in the CAR design, the researchers not only enhanced the killing ability of CAR - NK cells but also improved their migration and penetration ability in the complex tumor microenvironment. The research results show that this new CAR - NK cell therapy performs well in multiple in vitro models and has potential clinical application prospects.